By Brian Gleason in Therapeutic Philosophy — 04 Jun 2026

Which Psychedelic Is Right for You? (Wrong Question)

Everyone has a molecule

Spend enough time in the psychedelic world and you'll notice this immediately. People don't just use psilocybin or ayahuasca or ketamine. They identify with them. They become advocates, evangelists, cruise directors of altered states. They develop loyalties that would make sports fans blush. Ask someone at a plant medicine retreat what you should try and then buckle up. Because they will tell you, with the conviction of a convert and the specificity of a sommelier, exactly which compound will change your life, at what dose, in what setting, ideally under what moon.

It's endearing. It's also, in many ways, noise.

The pharmacology matters. The differences between a serotonergic psychedelic and a dissociative are real (I break the actual taxonomy down at the end, for the curious). If you're sitting in front of a clinical team weighing treatment options, the molecular details absolutely belong in the conversation. But if you're someone standing at the edge of this world, curious, nervous, maybe desperate, and very likely overwhelmed, the molecule question is almost certainly not the one you should be asking first.

I'll get to the questions that actually matter. But first, let's have some fun.

The Psychedelics Cheat Sheet

A warm who's-who of the molecules that shift reality.

Psilocybin Nicknames: Magic Mushrooms, Shrooms, Boomers Vibe: The cosmic jester who smells of wet soil. More than 200 species contain it, growing on every continent except Antarctica. Common sidekick: the giggles. It is the only molecule that can make you weep over the profound beauty of a dusty baseboard while suspecting your houseplant is definitely judging your life choices.

LSD Nicknames: Acid, Lucy, Tabs, Blotter Vibe: Hyper-structured chaos in technicolor. Steve Jobs meets kaleidoscopic geometry. Microgram-potent, meaning a grain of salt is too much. Can be your best friend or your math teacher's evil twin. The engineer's psychedelic.

Mescaline Nicknames: Peyote, San Pedro, Huachuma, Buttons, Cactus Vibe: The desert elder who has seen civilizations rise, fall, and make poor footwear choices. The first of these compounds Western science isolated, back in 1897, and the cactus alkaloid Aldous Huxley swallowed before writing The Doors of Perception. Ancient, sunlit, devotional, and allergic to being rushed. Less the engineer’s kaleidoscope, more a walk with a very old teacher who answers your most urgent question by pointing at a rock.

MDMA Nicknames: Molly, Ecstasy, The Heart Opener Vibe: The emotionally available rave therapist. Used legally in therapy until the 1985 ban, and nearly named "Empathy" before a distributor went with "Ecstasy" because it would move more product. Primary side effect: sudden desire to hug strangers. The relationship drug (or at least the DTR assistant).

Ayahuasca Nicknames: The Vine, Yagé, Aya, The Grandmother Vibe: The jungle shaman who sees your trauma before you do. Not one plant. It's a marriage of two (see DMT below). The vine provides the MAOI, and the leaf (chacruna) provides the DMT. The chemistry only works because of that union. Typical scene: buckets, singing, and the conviction you are simultaneously dying and being reborn. The stern but loving abuela of plant medicine.

Ketamine Nicknames: K, Special K, K-hole Vibe: The dissociative snowglobe. Originally a battlefield anesthetic, now used in clinics for depression and PTSD. Feels like floating inside a spaceship full of gentle nihilists. Good for breaking loops and watching your trauma from an emotionally safe balcony. The emergency exit.

Ibogaine Nicknames: The Root, The Scrub Brush of the Soul Vibe: The forensic auditor of your subconscious. Derived from the root bark of a Central African shrub, it is less of a "trip" and more of a 12-to-36-hour involuntary PowerPoint presentation of your every moral failing. While it has a reputation for shaking loose what nothing else can reach, it is not a magic wand. It is the stern uncle who forces you to sit in a dark room and stare at your own shadow until one of you blinks.

DMT Nicknames: The Spirit Molecule, Dimitri Vibe: The interstellar embassy. Smoked, it lasts about fifteen minutes. Swallowed in ayahuasca, it lasts hours. Either way, you may find yourself in a geometric palace being welcomed by entities who seem to have been expecting you. The most visual of all psychedelics. The one your friend who went to Peru won't stop talking about.

5-MeO-DMT Nicknames: The God Molecule, Five, Bufo (when from toad), Toad Vibe: Not DMT. Different molecule, different experience, different universe. Obliteration. Not ego death, ego disintegration. Found in the venom of the Incilius alvarius toad and in synthetic form. You don't journey with it. You vanish into it. The silent white light.

Now the Real Questions

Those descriptions are affectionate and they're mostly accurate. If they helped you feel a little less overwhelmed by the pharmacological alphabet soup, good. That was the point.

But here's what I actually want to talk about.

If you are standing at the edge of this world and trying to figure out whether to step in, you are almost certainly asking the wrong question. "Which psychedelic should I try?" feels like the obvious starting point. It isn't. It's actually the last question in a sequence of three, and the other two matter more.

First: Is a psychedelic even appropriate for you right now?

This is not a question about courage. It's a question about readiness, and readiness is biological as much as it is psychological.

Psychedelics are not universally safe. They are broadly safe for most people in supervised settings, which is a very different claim, and the distance between those two sentences is where people get hurt.

Some of the contraindications are well known. Psilocybin and LSD can be destabilizing for people with a personal or family history of psychotic disorders like schizophrenia or bipolar I. That's not a maybe. That's a hard stop. Ibogaine carries serious cardiac risks and requires an EKG and medical screening before anyone responsible will let you near it. And if you're currently taking an SSRI or SNRI, mixing those with ayahuasca isn't just inadvisable. It can produce serotonin syndrome, which can kill you. (MDMA carries its own serotonin interaction risks, particularly in combination with other serotonergic drugs.)

These aren't edge cases. They're common enough that any practitioner who doesn't ask about your medical history, your medications, and your psychiatric background before handing you a cup or a capsule is telling you everything you need to know about how seriously they take your safety.

But readiness goes beyond contraindications. There's a subtler question underneath, which is whether your body and your nervous system are in a state where they can actually make use of what a psychedelic opens up. If you are in acute crisis, sleep-deprived, physically depleted, or running on cortisol and caffeine, the experience may still happen. But your capacity to integrate it, to do something meaningful with it afterward, will be compromised. The biological context you bring into the room shapes the experience as much as the molecule does.

Second: Is the container right?

This is the question that matters most. I don't hear it asked enough.

"Container" is a word the psychedelic world uses to describe the total environment surrounding the experience: the physical space, the practitioners, the methodology, the safety protocols, and the plan for what happens before, during, and after the session. It is the difference between surgery performed in an operating room and surgery performed in a garage.

Here's what I'd want to know before trusting any program with my nervous system.

Does the team have a methodology they can explain to you? For some people, a well-held ceremonial experience with experienced facilitators and solid safety protocols is exactly the right setting. If you're exploring consciousness, processing something manageable, or simply curious, that may be all you need.

But if you're coming in with something heavier like treatment-resistant depression, deep trauma, patterns that have survived years of conventional therapy, then "we hold space and let the medicine do its work" is not a methodology. You deserve better than improvisation at the most psychologically open moment of your life.

Is there a plan for after? This is where most programs fail, and it's where the real work lives. These compounds open a window of heightened flexibility in the brain, where old patterns loosen and new ones become possible. It's real, it's measurable, and it doesn't stay open forever. If there's no structure waiting on the other side to help you work with what came up, the window closes and you're left with a powerful memory and not much else.

The experience is not the therapy. The experience is the opening. What you do with it is the therapy. Integration is the unsexy word for this, and it should mean something specific: directed, structured clinical work in the days and weeks after the session that helps you translate what was revealed into durable change. Not just reflection. Not just journaling and a weekly check-in call. Those things have a place, but if they're the whole plan, the plan isn't big enough. (I wrote about this gap in detail in After the Flood. If you're evaluating programs, that essay will give you a framework for knowing what questions to ask.)

If a program's entire emphasis is on the ceremony and they get vague when you ask what happens in week two, keep looking.

Third: Which molecule?

Now we can talk about this.

If you've done the work on the first two questions, this one largely answers itself. A competent clinical team working inside a well-designed program will guide you to the right compound based on your history, your goals, your medical profile, and the specific architecture of their process.

In practice this looks less exotic than people imagine. Someone reaches out with a history of treatment-resistant depression, a clean medical screen, and a nervous system that's been running hot for a decade. The serious programs aren't asking "which molecule do we reach for?" They already know what they work with and why. They're asking whether this particular person, with this particular history, is someone their model can actually help. Sometimes the answer is yes. Sometimes it's "not us, and here's who might be a better fit." The guests who do best are usually the ones who showed up curious rather than convinced, and who trusted the screening process to tell them something true.

The molecule tribalism I described at the top of this essay is real, and it comes from a genuine place. People have life-changing experiences with a particular substance and they want to share that. That's human. But the experience that changed their life happened inside a specific body, with a specific history, in a specific container. The molecule was one variable among many. Probably not the most important one.

The molecule is the easy part. The container is the hard part. And the container is what determines whether the experience becomes something that lasts.

One More Thing

There's a culture in some corners of the psychedelic world that equates depth with dose. Heroic doses. Breakthrough doses. The implication is always upward: more compound, more truth. If a little opened a door, a lot will blow the hinges off.

I understand the impulse. And I've watched it go wrong.

I once helped someone deal with the aftermath of a session that had everything right on paper. Good intentions. Solid preparation. An experienced facilitator in the room. In other words, a container that looked sound from the outside. But the dose was calibrated for spectacle rather than utility, and what came up in the session was more than the container could hold. Not more than the molecule could produce. More than the person could integrate. The weeks that followed weren't transformative. They were destabilizing. The gap between what was opened and what could be processed was too wide, and it had nothing to do with the chemistry, and everything to do with the dose.

A well-calibrated dose in a well-designed container will outperform a heroic dose in a miscalibrated one. Always. The goal is not to go as deep as possible. The goal is to go as deep as useful, and to have a structure that helps you bring something back.

So which psychedelic is right for you?

I don't know. But I can tell you this: the answer has almost nothing to do with the molecule.

A Note on the Taxonomy

I'm essentially drawing the line between the classic serotonergic psychedelics (most of the list) and ketamine. The distinction is real but goes deeper than this essay needs. At a high level:

The serotonergic psychedelics work primarily on serotonin receptors, especially 5-HT2A, and come in two structural families: tryptamines (psilocybin, DMT, 5-MeO-DMT, and the DMT inside ayahuasca, with LSD as a close ergoline cousin) and phenethylamines (mescaline). Different molecular shapes, same receptor.
MDMA is better classified as an empathogen/entactogen than a classical psychedelic. It works on serotonin too, but through a different mechanism, flooding the synapse with it rather than mimicking it at the receptor.
Ketamine is a dissociative (these work primarily by blocking NMDA glutamate receptors). It's the only one on the cheat sheet in that category.
Ibogaine is its own strange animal. It hits multiple receptor systems (opioid, NMDA, serotonin, sigma) and doesn't fit neatly into any camp. Most pharmacologists classify it separately.

References

For a clinically grounded introduction to how these psychedelic drugs work, Stephen Stahl's book is probably the best single starting point. For a more academic examination of integration in psychedelic therapy, Sascha Thal and colleagues reviewed 75 sources. Their conclusion is striking: rigorous research on integration is rare, and there's currently insufficient evidence to determine which framework works best.

Stahl, Stephen M. 2021. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Fifth edition. Cambridge University Press.

Thal, Sascha B., Paris Baker, Jonathon Marinis, et al. 2024. "Therapeutic Frameworks in Integration Sessions in Substance-Assisted Psychotherapy: A Systematised Review." Clinical Psychology & Psychotherapy 31 (1): e2945.